Great Basin Scientific (GBSN) Reports ~39% Increase in Prelim. Q2 Revenue; Installed Customer Base up 126%

Great Basin Scientific, Inc. (Nasdaq: GBSN) announced preliminary revenue results for the second quarter of 2016. For the second quarter of 2016, revenue was $728,957, an increase of 38.7% over the second quarter of 2015. Great Basin’s installed customer base is 260 as of June 30, 2016, an increase of 126.1% over the second quarter of last year.

Second Quarter 2016 Highlights:

• Entered into a $75MM convertible note financing
• 38 new customers added (see Exhibit 1)
  • 260 total customers
  • 253 C. diff customers
  • 78 Group B Strep customers
  • Group B Strep penetration increased to 30% of customers
• 516 Result Reporting Instruments at customer sites
• Revenues at existing customer sites declined seasonally from the first quarter to second quarter in 2016 due to decline in C. diff testing that occurs with the end of flu season
• Revenues at customer sites using the Great Basin system for at least one full year increased by 12% year-over-year, primarily due to a modest increase in C. diff testing and adoption of our Group B Strep test
• Commercial launch of Shiga Toxin Direct Test and Staph ID/R Panel delayed due to manufacturing validation, on-track to launch in the third quarter of this year
• Continued listing compliance plan accepted by Nasdaq’s Listing Qualifications Panel and an extension to regain compliance with the $35 million market value of listed securities requirement to October 10, 2016 was granted

“We are thrilled with our continued success in 2016 and are pleased to be ahead of plan for the year in securing revenue-producing customer sites,” said Ryan Ashton, co-founder and chief executive officer of Great Basin. “Our recently closed financing allows us to be more aggressive in both our instrument manufacturing plans and the expansion of our sales team, therefore we are raising our guidance for customer acquisition for both 2016 and 2017. As we look to double our menu of commercially available assays from two to four in the third quarter of 2016, we anticipate we will more than double our potential revenue per customer from $15,000 to approximately $35,000, with the caveat that not all our customers will use all our assays. We expect to see our revenue growth trajectory increase over the coming months, particularly in the second half of 2017 as our customers evaluate and add these assays to their diagnostic services.”

Conference Call

The Company will host a business update call to provide further details on its operational progress to-date and further guidance on corporate objectives today at 4:30 PM EDT. Great Basin invites all interested parties to join this call by dialing (877) 407-0789. For those who are not able to listen live, the transcript of the prepared remarks has been filed on a form 8-K with the securities and exchange commission and is also on the Investor Relations section of the Company’s website, www.gbscience.com.

*Company counts as “Customers” only labs that regularly place revenue-generating orders and use our assays to report results to clinicians

**30% of Customer sites are using more than one Assay

View source version on businesswire.com: http://www.businesswire.com/news/home/20160714006269/en/

Media:

ICR

Kate Ottavio Kent, 203-682-8276

[email protected]

or

Investor Relations:

CorProminence

Scott Gordon, 516-222-2560

[email protected]

or

ICR

David Clair, 646-277-1266

[email protected]

Source: Great Basin Scientific, Inc.

You May Also Be Interested In

• IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
• SeaChange (SEAC) Announces an Agreement to be Acquired by Enghouse and Termination of Previously Announced Proposed Acquisition by Partner One
• PENN Entertainment (PENN) Climbs after Hedge Fund Greenlight Takes Stake